Media

2026.04.08

G&E Herbal Biotechnology (4911), which focuses on new drug development, operates a complete PIC/S pharmaceutical plant, API plant, extraction plant, food plant, and cosmetics plant, making it one of Taiwan’s most forward-looking botanical drug developers. The company recently announced that its new drug SR-T100 injection (for treating malignant ascites in cancer patients) has received a reply from the Center for Drug Evaluation and will apply to the TFDA for a Phase I human clinical trial.

Chairman Kou-Hwa Kuo stated that following the company’s SR-T100 gel drug, which completed Phase III clinical trials in Taiwan and Phase II in the U.S. for actinic keratosis (early-stage skin cancer) and condyloma acuminatum, the newly developed SR-T100 injection for malignant ascites has now received positive feedback from the Center for Drug Evaluation’s clinical trial consultation. The company will submit an IND application to the Ministry of Health and Welfare’s TFDA for a Phase I human clinical trial.

Kuo explained that malignant ascites is a severe complication commonly seen during cancer treatment or in late-stage cancers, especially ovarian, gastric, colorectal, liver, and pancreatic cancers. Globally, there is no approved and effective drug for this condition. Current clinical management mainly relies on repeated paracentesis (fluid drainage) to temporarily relieve patient discomfort. Although more than a dozen international clinical trials have attempted to develop drugs for this indication, all were discontinued due to severe side effects or insufficient efficacy. This remains an urgent, unmet medical need.

G&E’s SR-T100 injection showed significant results in preclinical animal toxicology and pathology studies, leading to positive consultation feedback. The company is preparing to apply for Phase I clinical trials with TFDA. According to a report by Credence Research, the global malignant ascites market was valued at USD 1.122 billion in 2024 and is projected to grow to USD 2.269 billion by 2032.

Kuo emphasized that malignant ascites causes extreme abdominal distension, compressing the stomach and lungs, leading to difficulty eating and breathing. Even after drainage, fluid often reaccumulates within days, severely diminishing quality of life. Frequent drainage also results in malnutrition, cachexia, and infection.

Research indicates that once malignant ascites develops, patient survival averages only 1–3 months. If this condition can be alleviated, patients may at least maintain quality of life before passing, and improved eating and breathing could potentially extend survival. Guided by its mission to save lives, G&E Herbal Biotechnology is actively advancing the development of SR-T100 injection for malignant ascites.